Three years after formation, MiroBio is to be acquired by Gilead Sciences, Inc. for $405m, becoming the latest promising UK biotech to be snapped up by a major pharma firm.
The acquisition will provide Gilead with MiroBio’s proprietary discovery platform and entire portfolio of immune inhibitory receptor agonists. The Oxford...








